Mutated p.4894 RyR1 function related to malignant hyperthermia and congenital neuromuscular disease with uniform type 1 fiber (CNMDU1)

Anesthesia and Analgesia

Volumn 113, Issue 6, 2011, Pages 1461-1467

  Haraki, Toshiaki ^a   Yasuda, Toshimichi ^a   Mukaida, Keiko ^b   Migita, Takako ^a   Hamada, Hiroshi ^a   Kawamoto, Masashi ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b Hiroshima Prefectural Rehabilitation Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CAFFEINE; CALCIUM ION; DANTROLENE; RYANODINE RECEPTOR 1; SERINE; THREONINE;

ARTICLE; CALCIUM CELL LEVEL; CELL STRAIN HEK293; CONGENITAL NEUROMUSCULAR DISEASE WITH UNIFORM TYPE 1; GENE MUTATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALIGNANT HYPERTHERMIA; NEUROMUSCULAR DISEASE; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; CAFFEINE; CALCIUM; GENETIC VARIATION; HEK293 CELLS; HUMANS; MALIGNANT HYPERTHERMIA; MUSCLE FIBERS, SLOW-TWITCH; MUTAGENESIS, SITE-DIRECTED; NEUROMUSCULAR DISEASES; RABBITS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TRANSFECTION;

EID: 82255162766     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e318232053e     Document Type: Article

References (40)

1. Gillard E, Otsu K, Fujii J, Khanna V, de Leon S, Derdemezi J, Britt B, Duff C, Worton R, MacLennan D. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991;11:751-5
2. Ibarra MC, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi Y, Ochiai R, Nishino I. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006;104:1146-54 (Pubitemid 43852946)
3. Hamilton S. Ryanodine receptors. Cell Calcium 2005;38:253-60 (Pubitemid 41283263)
4. Stowell K. Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 2008;9:1657-72
5. Robinson R, Carpenter D, Shaw M, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006;27:977-89 (Pubitemid 44454050)
6. Lanner J, Georgiou D, Joshi A, Hamilton S. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2010;2:a003996
7. Vukcevic M, Broman M, Islander G, Bodelsson M, Ranklev- Twetman E, Müller C, Treves S. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease. Anesth Analg 2010;111: 185-90
8. McCarthy T, Quane K, Lynch P. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000;15:410-7 (Pubitemid 30331213)
9. Galli L, Orrico A, Lorenzini S, Censini S, Falciani M, Covacci A, Tegazzin V, Sorrentino V. Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia. Hum Mutat 2006;27:830
10. Sambuughin N, Holley H, Muldoon S, Brandom B, de Bantel A, Tobin J, Nelson T, Goldfarb L. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology 2005; 102:515-21 (Pubitemid 40315139)
11. Levano S, Vukcevic M, Singer M, Matter A, Treves S, Urwyler A, Girard T. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009;30:590-8
12. Quane K, Healy J, Keating K, Manning B, Couch F, Palmucci L, Doriguzzi C, Fagerlund T, Berg K, Ording H. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Genet 1993;5:51-5 (Pubitemid 23261518)
13. Zhang Y, Chen H, Khanna V, De Leon S, Phillips M, Schappert K, Britt B, Browell A, MacLennan D. A mutation in the human ryanodine receptor gene associated with central core disease. Nat Genet 1993;5:46-50 (Pubitemid 23261517)
14. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella- Branger D, Roméro N, Mezin P, Bendahan D, Payen J, Depret T, Maclennan D, Lunardi J. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005;26:413-25 (Pubitemid 41572448)
15. Oh S, Danon M. Nonprogressive congenital neuromuscular disease with uniform type 1 fiber. Arch Neurol 1983;40:147-50 (Pubitemid 13139114)
16. Sato I, Wu S, Ibarra M, Hayashi Y, Fujita H, Tojo M, Oh S, Nonaka I, Noguchi S, Nishino I. Congenital neuromuscular disease with uniform type 1 fiber and RYR1 mutation. Neurology 2008;70:114-22
17. Tojo M, Ozawa M, Nonaka I. Central core disease and congenital neuromuscular disease with uniform type 1 fibers in one family. Brain Dev 2000;22:262-4 (Pubitemid 30323842)
18. Migita T, Mukaida K, Hamada H, Yasuda T, Haraki T, Nishino I, Murakami N, Kawamoto M. Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon 47. J Anesth 2009;23:341-6
19. 2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease. J Biol Chem 1997;272:26332-9 (Pubitemid 27458847)
20. 2+ release channel (ryanodine receptor). Biophys J 1997;73:1904-12 (Pubitemid 27425721)
21. Krause T, Gerbershagen M, Fiege M, Weisshorn R, Wappler F. Dantrolene: a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364-73 (Pubitemid 38489297)
22. Treiman M, Caspersen C, Christensen S. A tool coming of age: thapsigargin as an inhibitor of sarco-endoplasmic reticulum Ca(2-)-ATPases. Trends Pharmacol Sci 1998;19:131-5 (Pubitemid 28218535)
23. 2+ release channels. J Biol Chem 1999;274: 693-702
24. Endo M, Tanaka M, Ogawa Y. Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 1970;228:34-6
25. Endo M. Calcium-induced calcium release in skeletal muscle. Physiol Rev 2009;89:1153-76
26. Oku S, Mukaida K, Nosaka S, Sai Y, Maehara Y, Yuge O. Comparison of the in vitro caffeine-halothane contracture test with the Ca-induced Ca release rate test in patients suspected of having malignant hyperthermia susceptibility. J Anesth 2000;14:6-13 (Pubitemid 30189424)
27. 2+ release channel function and severe central core disease. Proc Natl Acad Sci USA 1999;96:4164-9 (Pubitemid 29169054)
28. Avila G, Dirksen R. Functional effects of central core disease mutations in the cytoplasmic region of the skeletal muscle ryanodine receptor. J Gen Physiol 2001;118:277-90 (Pubitemid 32845963)
29. Dirksen R, Avila G. Altered ryanodine receptor function in central core disease: leaky or uncoupled Ca(2-) release channels? Trends Cardiovasc Med 2002;12:189-97 (Pubitemid 34823628)
30. Avila G, OConnell K, Dirksen R. The pore region of the skeletal muscle ryanodine receptor is a primary locus for excitation-contraction uncoupling in central core disease. J Gen Physiol 2003;121:277-86 (Pubitemid 36418572)
31. Ramachandran S, Serohijos A, Xu L, Meissner G, Dokholyan N. A structural model of the pore-forming region of the skeletal muscle ryanodine receptor (RyR1). PLoS Comput Biol 2009;5:e1000367
32. Gao L, Balshaw D, Xu L, Tripathy A, Xin C, Meissner G. Evidence for a role of the lumenal M3-M4 loop in skeletal muscle Ca(2-) release channel (ryanodine receptor) activity and conductance. Biophys J 2000;79:828-40
33. Zhao M, Li P, Li X, Zhang L, Winkfein R, Chen S. Molecular identification of the ryanodine receptor pore-forming segment. J Biol Chem 1999;274:25971-4
34. Treves S, Jungbluth H, Muntoni F, Zorzato F. Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. Curr Opin Pharmacol 2008;8:319-26
35. Tilgen N, Zorzato F, Halliger-Keller B, Muntoni F, Sewry C,Palmucci L, Schneider C, Hauser E, Lehmann-Horn F, Müller C, Treves S. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001;10:2879-87 (Pubitemid 34030919)
36. Davis M, Haan E, Jungbluth H, Sewry C, North K, Muntoni F, Kuntzer T, Lamont P, Bankier A, Tomlinson P, Sánchez A, Walsh P, Nagarajan L, Oley C, Colley A, Gedeon A, Quinlivan R, Dixon J, James D, Müller C, Laing N. Principal mutation hotspot for central core disease and related myopathies in the C-terminal transmembrane region of the RYR1 gene. Neuromuscul Disord 2003;13:151-7 (Pubitemid 36140010)
37. Shepherd S, Ellis F, Halsall J, Hopkins P, Robinson R. RYR1 mutations in UK central core disease patients: more than just the C-terminal transmembrane region of the RYR1 gene. J Med Genet 2004;41:e33
38. Ma J, Pan Z. Retrograde activation of store-operated calcium channel. Cell Calcium 2003;33:375-84 (Pubitemid 36748660)
39. Parekh AB, Putney JW. Store-operated calcium channels. Physiol Rev 2005;85:757-810 (Pubitemid 40404641)
40. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J. Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem 2006;281:33477-86 (Pubitemid 46036729)